Biocartis to Present Breast Cancer Assay Data in December
The company will unveil Idylla Breast21 results at the San Antonio Breast Cancer Symposium.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you believe decentralized diagnostic testing improves patient access to timely medical care?
Biocartis will present development data for its Idylla Breast21 Assay at the San Antonio Breast Cancer Symposium, scheduled for December 8-11, 2026. The study demonstrates the prototype's ability to achieve risk class agreement with an established 21-gene recurrence score.
Why it matters
Current breast cancer recurrence risk testing relies on centralized laboratory services that can extend the time needed for treatment decisions. A decentralized, fully automated system could significantly shorten that process for patients and clinicians.
The Idylla Breast21 Assay uses a fully automated RT-PCR process to analyze RNA expression from 21 genes in FFPE tissue. The system is designed to deliver a recurrence-risk score in less than 4 hours.
The players
Biocartis
A healthcare company based in Mechelen, Belgium, that develops molecular diagnostics platforms.
The details
The Idylla Breast21 Assay functions as a fully automated and decentralized platform for testing breast cancer tissue samples. By processing tissue locally, the system aims to provide rapid diagnostic information directly to healthcare providers.
Timeline
October 30, 2026: Biocartis announced the acceptance of its study abstract.
December 8-11, 2026: The San Antonio Breast Cancer Symposium will take place in Texas.
The Tech Race
The transition from centralized laboratory testing to decentralized, rapid diagnostic platforms represents a major shift in clinical oncology workflows. This move mirrors broader efforts to reduce patient wait times by integrating automated molecular testing directly into hospital environments.
Patients may eventually see a reduction in the time they spend waiting for critical cancer recurrence test results. The shift to a faster, 4-hour processing time could allow for more efficient treatment planning and fewer delays in care.
The takeaway
Advancements in decentralized diagnostic tools could transform how quickly clinicians receive essential recurrence risk data. Streamlining these laboratory processes is a key step toward improving the speed of personalized cancer treatment plans.
Further reading
Learn more about the latest industry developments at Biotech.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe decentralized diagnostic testing improves patient access to timely medical care?
